Regentis Biomaterials Ltd. (NYSE American: RGNT), a regenerative medicine company focused on innovative tissue repair solutions, reported financial results for the six months ended June 30, 2026, and provided a corporate and clinical update. The company has recruited and treated 43 of 80 patients in its pivotal Phase III GelrinC U.S. trial and now expects to complete enrollment around year-end. This progress is crucial as GelrinC aims to address a market of approximately 470,000 cartilage knee repair cases annually in the U.S. where no off-the-shelf treatment is available.
The company also expanded its U.S. and European clinical networks, advanced preparations for European commercialization, and received regulatory approval in Europe for a new solvent-free manufacturing process that increases GelrinC production yield by 400%. This approval is a major milestone that could significantly reduce production costs and scale up supply for both clinical and future commercial needs. The yield increase demonstrates Regentis' commitment to efficient manufacturing, which is essential for a cost-effective rollout in competitive markets.
For the first half, Regentis reported a net loss of approximately $2.6 million, or $0.44 per share, compared with approximately $3.2 million, or $1.17 per share, a year earlier. The reduced loss reflects ongoing efforts to manage expenses while advancing clinical programs. The company completed a $6.5 million private placement in June and ended the period with approximately $9 million in cash and cash equivalents and no debt. This financial position provides runway to reach key milestones, including the completion of enrollment in the pivotal trial and further regulatory progress in Europe.
Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore health and enhance quality of life. With an initial focus on orthopedic treatments, Regentis’ Gelrin platform technology, based on synchronized, degradable hydrogel implants, regenerates damaged or diseased tissue including inflamed cartilage and bone. Regentis’ lead product GelrinC, is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing the surrounding cells to regenerate the cartilage in a controlled and synchronous process. GelrinC aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S. where no off-the-shelf treatment is available.
For investors, the latest news and updates relating to RGNT are available in the company’s newsroom at https://ibn.fm/RGNT. To view the full press release, visit https://ibn.fm/TUedB. These updates are part of a paid investor awareness and marketing engagement, and further information about BioMedWire’s services can be found at https://www.BioMedWire.com.
